Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

1.650 -0.030 (-1.79%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 130,962
Open 1.700
Bid (Size) 1.640 (2)
Ask (Size) 1.770 (8)
Prev. Close 1.680
Today's Range 1.640 - 1.750
52wk Range 0.5116 - 2.450
Shares Outstanding 36,382,989
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire

Performance

YTD
-12.2%
-12.2%
1 Month
N/A
N/A
3 Month
+46.0%
+46.0%
6 Month
+3.1%
+3.1%
1 Year
+122.4%
+122.4%

More News

Read More
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
From Quince Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Top movers in Wednesday's after hours session
Via Chartmill
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Quince Therapeutics to Present at Citizens Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga

Frequently Asked Questions

Is Quince Therapeutics, Inc. - Common Stock publicly traded?
Yes, Quince Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Quince Therapeutics, Inc. - Common Stock trade on?
Quince Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Quince Therapeutics, Inc. - Common Stock?
The ticker symbol for Quince Therapeutics, Inc. - Common Stock is QNCX on the Nasdaq Stock Market
What is the current price of Quince Therapeutics, Inc. - Common Stock?
The current price of Quince Therapeutics, Inc. - Common Stock is 1.650
When was Quince Therapeutics, Inc. - Common Stock last traded?
The last trade of Quince Therapeutics, Inc. - Common Stock was at 07/30/25 04:00 PM ET
What is the market capitalization of Quince Therapeutics, Inc. - Common Stock?
The market capitalization of Quince Therapeutics, Inc. - Common Stock is 60.03M
How many shares of Quince Therapeutics, Inc. - Common Stock are outstanding?
Quince Therapeutics, Inc. - Common Stock has 60M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.